Pharmacokinetic and Pharmacodynamic of Rocuronium

Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

Inclusion Criteria:

• Scheduled for elective surgery under general anesthesia.

Exclusion Criteria:

• Pregnancy.
• Body mass index (BMI) >25 kg/m2.
• Anticipated difficult airway.
• Surgery associated with great volume loss.
• Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease.
• Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade